Based on the Spyre Therapeutics Inc. stock forecast from 5 analysts, the average analyst target price for Spyre Therapeutics Inc. is USD 53.14 over the next 12 months. Spyre Therapeutics Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Spyre Therapeutics Inc. is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Spyre Therapeutics Inc.’s stock price was USD 15.07. Spyre Therapeutics Inc.’s stock price has changed by +3.65% over the past week, +7.95% over the past month and -57.61% over the last year.
No recent analyst target price found for Spyre Therapeutics Inc.
No recent average analyst rating found for Spyre Therapeutics Inc.
Company Overview Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Read Less
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin bei...Read More
Frequently Asked Questions About Spyre Therapeutics Inc. (SYRE) Stock
Based on ratings from 5 analysts Spyre Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on SYRE's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SYRE is USD 53.14 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 27.
SYRE stock's Price/Earning ratio is 1.72.
Our analysis grades SYRE stock's Price / Earning ratio at D. This means that SYRE stock's Price/Earning ratio is above 34% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SYRE may be fairly valued for its sector
The last closing price of SYRE's stock was USD 15.07.
The most recent market capitalization for SYRE is USD 0.88B.
Based on targets from 5 analysts, the average taret price for SYRE is projected at USD 53.14 over the next 12 months.
This means that SYRE's stock price may go up by +252.64% over the next 12 months.
We can't find any ETFs which contains Spyre Therapeutics Inc.'s stock.
As per our most recent records Spyre Therapeutics Inc. has 73 Employees.
Spyre Therapeutics Inc.'s registered address is 221 Crescent Street, Waltham, MA, United States, 02453.
You can get more information about it from Spyre Therapeutics Inc.'s website at https://www.spyre.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Spyre Therapeutics Inc. (SYRE) Stock
Based on ratings from 5 analysts Spyre Therapeutics Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on SYRE's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SYRE is USD 53.14 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 27.
SYRE stock's Price/Earning ratio is 1.72.
Our analysis grades SYRE stock's Price / Earning ratio at D. This means that SYRE stock's Price/Earning ratio is above 34% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SYRE may be fairly valued for its sector
The last closing price of SYRE's stock was USD 15.07.
The most recent market capitalization for SYRE is USD 0.88B.
Based on targets from 5 analysts, the average taret price for SYRE is projected at USD 53.14 over the next 12 months.
This means that SYRE's stock price may go up by +252.64% over the next 12 months.
We can't find any ETFs which contains Spyre Therapeutics Inc.'s stock.
As per our most recent records Spyre Therapeutics Inc. has 73 Employees.
Spyre Therapeutics Inc.'s registered address is 221 Crescent Street, Waltham, MA, United States, 02453.
You can get more information about it from Spyre Therapeutics Inc.'s website at https://www.spyre.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SYRE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
